It is World Allergy Week and this year’s theme is The Global Problem of Food Allergy. To help us take action on food allergies, we are seeking 1,000 individuals to fill out a survey that may take 15-30 minutes to complete (the length of the survey depends on your answers).
College students with food allergies now have an easier way to find safe meal choices. This is thanks to a recent agreement between the U.S. Department of Justice (DOJ) and Rider University in Lawrenceville, New Jersey.
A lot of questions remain about long-term allergy outcomes following immunotherapy. A new study presented at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting has found that the ability to incorporate peanut food equivalents into the diet is maintained years after completing food immunotherapy.
Even baked-egg tolerant children may see better results when treated with egg oral immunotherapy (OIT) instead of the addition of baked-egg products into their daily diets.
Peanut allergies can lead to severe allergic reactions, but everyday factors that may influence an allergic reaction are poorly understood. A new study, first presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), is trying to change that.
A study presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) has found that certain patients treated with egg oral immunotherapy (OIT) are likely to continue consuming and tolerating egg five years after treatment.
Sesame allergy appears increasingly common among United States children and adults, with new research establishing it as the ninth most common type of food allergy.
A new oral immunotherapy (OIT) treatment using boiled peanut has been found to be both effective and safe, following a Phase 2b/3 randomized controlled trial.
DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
Researchers at National Jewish Health and their colleagues have identified structural and molecular markers in the skin of atopic dermatitis patients that distinguish those who have food allergies from those who do not. The findings strengthen emerging science indicating that the skin plays a major role in food allergies, and suggest that personalized treatments for a subset of atopic dermatitis patients might help prevent food allergies.
Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of PeanutAllergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, February 13th, at 4:30 ET / 22:30 CET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
DBV Technologies today announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. DBV is currently working closely with the agency to resubmit the application for Viaskin Peanut as quickly as possible.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019. The publically-available Wholesale Acquisition Cost (WAC)2
People with food allergies know eating at a restaurant means using multiple strategies to make sure your order doesn’t contain something that could send you to the hospital with anaphylaxis – a severe life-threatening reaction.
The final research results for a new treatment for protection against accidental exposure to peanut was presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine. The results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.